Amgen Further Narrows Patient Population For Its EGFR Inhibitor In Colon Cancer
Executive Summary
In new analyses of previous studies, Amgen finds that metastatic colon cancer with any RAS mutations – not just KRAS – doesn’t respond well to EGFR inhibition. The company is discussing the data with regulators.